

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW WASHINGTON, DC
WASHINGTON, DC 20004-2401 NEW YORK
TEL 202.662.6000 LONDON
FAX 202.662.6291 BRUSSELS
WWW.COV.COM SAN FRANCISCO

PAUL J. BERMAN
TEL 202.662.5468
FAX 202.778.5468
PBERMAN@COV.COM



April 16, 2001

Box Patent Application

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: New U.S. Non-Provisional Utility Patent Application
Appl. No.: To be assigned; Filed: Herewith
Continuation of U.S. Appl. No. 08/797,294; Filed: February 7, 1997
For: Aminosugar, Glycosaminoglycan, and S-Adenosylmethionine
Composition for the Treatment and Repair of Connective Tissue
Inventors: Robert W. Henderson and Tarek Hammad
Our Ref: 24047.330C.US01

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a **continuation** application of prior Appl. No. 08/797,294, consisting of the following documents:

1. Patent Application Initial Information Data Sheet;
2. Utility Patent Application Transmittal Form PTO/SB/05;
3. U.S. Utility Patent Application, entitled:

Aminosugar, Glycosaminoglycan, and S-Adenosylmethionine
Composition for the Treatment and Repair of Connective Tissue

and naming as inventors:

Robert W. Henderson and Tarek Hammad

the application comprising:

- a. The specification containing:
 - (i) 35 pages of description prior to the claims;

COVINGTON & BURLING

Assistant Commissioner for Patents

April 16, 2001


Page 2

- (ii) 3 pages of claims (13 claims);
- (iii) a one (1) page abstract;
- b. Three sheets of drawings: (Figures 1-3);
- c. Copy of the executed inventors' Declaration from prior application no. 08/797,294;
- 4. Copy of the Verified Statement Claiming Small Entity Status (37 C.F.R. 1.9(f) & 1.27(b))--Independent Inventor executed by the inventors from prior application no. 08/797,294;
- 5. Copy of the Verified Statement Claiming Small Entity Status (37 CFR 1.27(b))--Assignee of Independent Inventor from prior application no. 08/797,294;
- 6. Preliminary Amendment;
- 7. An Information Disclosure Statement (IDS);
- 8. Form PTO-1449; and
- 9. Two return receipt postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without without filing fee.

Respectfully submitted,





Paul J. Berman (Reg. No. 36,253)

Enclosures

Please type a plus sign (+) inside this box →

PTO/SB/05 (2/98)
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(h))</i>		Attorney Docket No. 24047.330C.US01	
		First Named Inventor or Application Identifier Robert W. Henderson	
		Title Aminosugar, Glycosaminoglycan, and S-Adenosylmethionine Composition for the Treatment and Repair of Connective Tissue	
		Express Mail Label No.	
APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>		Assistant Commissioner for Patents ADDRESS TO: Box Patent Application Washington, DC 20231	
<p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17)</p> <p>2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages 39] <i>(preferred arrangement set forth below)</i> -Descriptive title of the invention -Cross Reference to Related Applications -Statement Regarding Fed sponsored R & D -Reference to sequence listing, a table, or a computer program listing appendix -Background of the Invention -Brief Summary of the Invention -Brief Description of the Drawings <i>(if filed)</i> -Detailed Description -Claim(s) -Abstract of the Disclosure</p> <p><input checked="" type="checkbox"/> Drawing(s) <i>((35 U.S.C. 113))</i> [Total Sheets 3]</p> <p>5. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 1] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p>		<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program <i>(Appendix)</i></p> <p>8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies</p>	
ACCOMPANYING APPLICATION PARTS			
<p>9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i></p> <p>12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>17. <input checked="" type="checkbox"/> Other: Verified Statements Claiming Small Entity Status</p>			
<p>18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 08/797,294 Prior Application Information: Examiner: E. White Group/Art Unit: 1623</p>			
<p>For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.</p>			
19. CORRESPONDENCE ADDRESS			
<p><input checked="" type="checkbox"/> Customer Number or Bar Code Label  or <input type="checkbox"/> Correspondence address below <i>(Insert Customer No. or Address Bar Code label here)</i></p>			
NAME		Patent Docketing 26853	
ADDRESS		COVINGTON & BURLING PATENT, TRADEMARK OFFICE	
CITY		Washington	STATE
COUNTRY		US	TELEPHONE
		DC	ZIP CODE
		202-662-6000	FAX
			202-662-6291
Name (Print/Type)		Paul J. Berman	
Signature			
		Registration No. (Attorney/Agent)	36,744
		Date	April 16, 2001